...
首页> 外文期刊>Intensive care medicine >Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.
【24h】

Conversion of recent-onset atrial fibrillation or flutter with ibutilide after amiodarone has failed.

机译:胺碘酮治疗失败后,用伊布利特将新近发生的心房纤颤或扑动转变。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AbstractOBJECTIVE. To evaluate whether ibutilide can convert atrial fibrillation or flutter in patients in whom amiodarone has failed.DESIGN AND SETTING. Clinical study in a university hospital intensive care unit (ICU).PATIENTS. Twenty-six patients were studied, in whom atrial fibrillation or flutter persisted for a maximum of 6 h at maximum. Patients were monitored continuously during the arrhythmia. Medical conversion was necessary due to symptomatic or hemodynamic causes.INTERVENTIONS. All patients initially received amiodarone (150 mg i.v.) and after 2 h of persistent arrhythmia ibutilide (1 mg or, without success and body weight >70 kg, 2 mg i.v.). Before the administration of ibutilide 1 g magnesium was administered, and high normal levels of potassium serum levels were achieved (4.5-5.0 mmol/l).RESULTS. After amiodarone atrial flutter persisted in 73% and atrial fibrillation in 27% of patients. After ibutilide the QT interval was prolonged from 327+/-61 to 387+/-62 ms. The QTc interval increased from 456+/-32 to 461+/-66 ms. Conversion to normal sinus rhythm was achieved in 22 of 27 of cases. Nonsustained torsade de pointes tachycardia was seen in three patients (11%). No patient showed sustained ventricular tachycardia. Patients with proarrhythmic effects were characterized by a decreased left ventricular function.CONCLUSIONS. In ICU patients ibutilide led to conversion to sinus rhythm in 81.5% of patients in whom amiodarone was unsuccessful. Nonsustained tachycardias were seen in 11%; sustained ventricular tachycardia was not seen. Ibutilide seems to be well suitable for conversion of recent onset atrial fibrillation or flutter and had no severe side effects in this study population.
机译:摘要目标。在胺碘酮治疗失败的患者中评估伊布利特是否可以使房颤或扑动转变。设计与设置。在大学医院重症监护室(ICU)中进行临床研究。研究了26例患者,其中房颤或扑动持续最多6 h。在心律不齐期间持续监测患者。由于症状或血液动力学原因,必须进行医学转换。干预措施。所有患者最初均接受胺碘酮(150 mg静脉内)治疗,持续2小时后持续服用伊布利特(1 mg或体重> 70 kg,但未成功且体重不超过70 kg的静脉注射2 mg)。在施用伊布利特之前,先施用1 g镁,并达到高的正常血清钾水平(4.5-5.0 mmol / l)。胺碘酮治疗后,房扑持续存在73%,房颤持续发生在27%的患者中。依非利特治疗后,QT间隔从327 +/- 61延长至387 +/- 62 ms。 QTc间隔从456 +/- 32毫秒增加到461 +/- 66毫秒。 27例病例中有22例转变为正常窦性心律。在三名患者(11%)中观察到了非持续性的点状心动过速。没有患者表现出持续性室性心动过速。具有心律失常作用的患者的特征在于左心室功能降低。在ICU患者中,乙胺碘胺导致胺碘酮治疗失败的患者中有81.5%的患者转变为窦律。 11%的患者出现非持续性心动过速;未见持续性室性心动过速。伊布利特似乎很适合于近期发作的心房纤颤或扑动的转化,并且在该研究人群中没有严重的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号